惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

腾讯CDC
让小产品的独立变现更简单 - ezindie.com
让小产品的独立变现更简单 - ezindie.com
P
Proofpoint News Feed
D
DataBreaches.Net
D
Docker
云风的 BLOG
云风的 BLOG
大猫的无限游戏
大猫的无限游戏
月光博客
月光博客
J
Java Code Geeks
钛媒体:引领未来商业与生活新知
钛媒体:引领未来商业与生活新知
OSCHINA 社区最新新闻
OSCHINA 社区最新新闻
罗磊的独立博客
Martin Fowler
Martin Fowler
U
Unit 42
Engineering at Meta
Engineering at Meta
IT之家
IT之家
Vercel News
Vercel News
B
Blog RSS Feed
人人都是产品经理
人人都是产品经理
博客园 - Franky
博客园 - 【当耐特】
Stack Overflow Blog
Stack Overflow Blog
G
Google Developers Blog
MongoDB | Blog
MongoDB | Blog

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
GRAIL, Inc. (GRAL) Presents at Bank of America Global Hea...
2026-05-13 · via All Articles on Seeking Alpha

Q1: 2026-05-05 Earnings Summary

EPS of -$1.37 beats by $0.59

 | 

Revenue of

$40.79M

(28.11% Y/Y)

beats by $1.63M

GRAIL, Inc. (GRAL) Bank of America Global Healthcare Conference 2026 May 12, 2026 11:40 AM EDT

Company Participants

Aaron Freidin - Chief Financial Officer

Conference Call Participants

Michael Ryskin - BofA Securities, Research Division

Conversation

Aaron Freidin
Chief Financial Officer

[Audio Gap] Our digital health channels. It's been great to see there despite some of the NHS headlines, the growth persisted and so on. So really excited to be there. For the rest of the year, we've got -- we've announced we're going to implement Epic by the end of the year. We continue to see momentum from some of our other integrations, whether it's Quest or Athenahealth and the pull-through is there. So it's great to see...

Michael Ryskin
BofA Securities, Research Division

Maybe let's -- you mentioned NHS. -- let's just dive right into that. That was sort of the big update that happened during the quarter. A lot to parse apart there. Has that impacted any of your customers or in your conversations around demand? So has that had any impact on the business as you see it in terms of like volume?

Aaron Freidin
Chief Financial Officer

Yes. So I'd say that the headline came out and physicians who are orderers, physicians who are prospective orderers ask more questions. It was pretty clear though that those who saw beyond the headline and saw some of the clinical utility measures such as Stage IV reduction, increase in Stage I and II, decreased emergency room presentations, 4x more cancers found than the standard of care, like they got it. That all being said, everyone wants to see the data at ASCO. It's one of those SEC disclosure type things where you've got data in-house, you've got to say something vague, to not protect your -- I mean, to not ruin your ASCO presentation. So everybody wants to see the ASCO data, and that will